KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Retained Earnings (2016 - 2025)

Jazz Pharmaceuticals has reported Retained Earnings over the past 16 years, most recently at $646.2 million for Q4 2025.

  • Quarterly results put Retained Earnings at $646.2 million for Q4 2025, up 168.19% from a year ago — trailing twelve months through Dec 2025 was $646.2 million (up 168.19% YoY), and the annual figure for FY2025 was $646.2 million, up 168.19%.
  • Retained Earnings for Q4 2025 was $646.2 million at Jazz Pharmaceuticals, up from $442.7 million in the prior quarter.
  • Over the last five years, Retained Earnings for JAZZ hit a ceiling of $974.3 million in Q3 2022 and a floor of -$1.1 billion in Q4 2022.
  • Median Retained Earnings over the past 5 years was -$294.2 million (2021), compared with a mean of -$91.8 million.
  • Peak annual rise in Retained Earnings hit 634.67% in 2022, while the deepest fall reached 479.27% in 2022.
  • Jazz Pharmaceuticals' Retained Earnings stood at -$400.4 million in 2021, then tumbled by 181.12% to -$1.1 billion in 2022, then skyrocketed by 178.07% to $878.7 million in 2023, then tumbled by 207.85% to -$947.7 million in 2024, then skyrocketed by 168.19% to $646.2 million in 2025.
  • The last three reported values for Retained Earnings were $646.2 million (Q4 2025), $442.7 million (Q3 2025), and -$485.8 million (Q2 2025) per Business Quant data.